Search

Your search keyword '"Costantino Zampaletta"' showing total 2 results
Start Over Author "Costantino Zampaletta" Journal journal of gastrointestinal and liver diseases : jgld
2 results on '"Costantino Zampaletta"'

1. Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy

Author

Costantino Zampaletta, Alessandro Armuzzi, Laura Turchini, Elisa Schiavoni, Daniela Pugliese, Daniele Napolitano, Mariaelena Serio, Antonella Scarcelli, Ladislava Sebkova, Rodolfo Sacco, Stefano Rodino’, Giuseppe Pranzo, Roberta Pica, Patrizia Perazzo, Cristiano Pagnini, Rita Monterubbianesi, Costantino Meucci, Francesco Luzza, Marco Le Grazie, Camilla Graziosi, Laura Donnarumma, Gianluigi De’ Angelis, Andrea Cocco, Valeria Clemente, Stefania Chiri, Alessia Immacolata Cazzato, Gabrio Bassotti, Antonio Penna, Tiziana Larussa, Roberto Lorenzetti, Katia Lofano, Maria Giovanna Graziani, GianMarco Giorgetti, Federica Gaiani, Giacomo Forti, Roberto Faggiani, Nicola Della Valle, Raffaele Colucci, Maria Antonia Bianco, Giovanni Aragona, Leonardo Allegretta, Italian group for switch of biologics, Alfredo Papa, Franco Scaldaferri, Giovanni Maconi, Marcello Picchio, Walter Elisei, Antonio Ferronato, Antonio Cuomo, Giammarco Mocci, and Antonio Tursi

Subjects
Treatment Outcome, Italy, Gastroenterology, Adalimumab, Humans, Inflammatory Bowel Diseases, Biosimilar Pharmaceuticals, Infliximab, Retrospective Studies
Abstract

Background and Aims: Adalimumab (ADA) biosimilars have been included into the therapeutic armamentarium of inflammatory bowel disease (IBD); however, comparative data on the efficacy and safety of the different ADA biosimilars after replacing the ADA originator for a non-medical reason remains scarce. We aimed to compare in a real-life setting the efficacy and safety of four ADA biosimilars SB5, APB501, GP2017, and MSB11022 in IBD patients after replacing the originator for a non-medical reason. Methods: A multicenter retrospective study was performed on consecutive IBD patients, analyzing clinical, laboratory, and endoscopic data. The primary endpoints of the study were maintenance of clinical remission and safety of the different biosimilars. Results: 153 patients were enrolled, 26 with UC and 127 with CD. Clinical remission was maintained in 124 out of 153 (81%) patients after a median (IQR) follow-up of 12 (6–24) months, without any significant difference between the four ADA biosimilars. ADA biosimilars dosage was optimized in five patients (3.3%). Loss of remission was significantly higher in UC patients (10/26 patients, 38.5%) than in CD patients (19/127 patients, 14.9%, p

Published
2022

2. Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers

Author

Nicola Della Valle, Giacomo Forti, Roberto Lorenzetti, Nello Buccianti, Giuseppe Pranzo, Marcello Picchio, C. Ricciardelli, Costantino Zampaletta, Francesco Luzza, A. Lauria, Leonardo Allegretta, Walter Elisei, Antonio Tursi, Tiziana Larussa, Natale Polimeni, Antonio Penna, Roberto Faggiani, Sara Gallina, Yusef Hadad, and G. Mocci

Subjects
Adult, Male, medicine.medical_specialty, Time Factors, medicine.medical_treatment, Anti-Inflammatory Agents, Gastroenterology, 03 medical and health sciences, Feces, 0302 clinical medicine, Gastrointestinal Agents, Interquartile range, Internal medicine, medicine, Adalimumab, Ambulatory Care, Humans, Prospective Studies, Colitis, Intestinal Mucosa, Colectomy, Wound Healing, business.industry, Remission Induction, Antibodies, Monoclonal, Middle Aged, medicine.disease, Ulcerative colitis, Infliximab, Golimumab, C-Reactive Protein, Treatment Outcome, Italy, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Colitis, Ulcerative, Female, Steroids, Calprotectin, Inflammation Mediators, business, Leukocyte L1 Antigen Complex, medicine.drug
Abstract

Background & Aims: Golimumab (GOL) has been recently approved in Italy for the treatment of ulcerative colitis (UC) unresponsive to standard treatments. Our aims were to assess the real-life efficacy and safety of GOL in managing UC outpatients in Italian primary Inflammatory Bowel Diseases (IBD) centres.Methods: Consecutive UC outpatients with at least 3-months follow-up were enrolled. Primary end-point was the induction and maintenance of remission in UC, defined as Mayo score ≤2, at 6-month follow-up.Results: Ninety-three patients were enrolled. At 6-month follow-up, remission was obtained in 34 (36.5%) patients. Shorter duration of disease was the only significant predictive factor of remission. Clinical response was achieved in 60 (64.5%) patients, while mucosal healing (MH) was obtained in 18 (19.3%) patients. Sixteen (47.0%) patients under remission were still under therapy with steroids. C-reactive protein and fecal calprotectin significantly dropped during the follow-up (p

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results